Astrazeneca PLC (AZN) Position Boosted by Blair William & Co. IL
Blair William & Co. IL increased its stake in shares of Astrazeneca PLC (NYSE:AZN) by 62.3% during the second quarter, according to its most recent filing with the SEC. The institutional investor owned 42,117 shares of the company’s stock after buying an additional 16,174 shares during the period. Blair William & Co. IL’s holdings in Astrazeneca PLC were worth $1,436,000 as of its most recent SEC filing.
A number of other hedge funds also recently added to or reduced their stakes in the stock. Salem Investment Counselors Inc. bought a new stake in Astrazeneca PLC during the first quarter valued at $107,000. Meeder Asset Management Inc. bought a new stake in Astrazeneca PLC during the second quarter valued at $105,000. Tower Research Capital LLC TRC boosted its stake in Astrazeneca PLC by 3,782.0% in the first quarter. Tower Research Capital LLC TRC now owns 3,882 shares of the company’s stock valued at $121,000 after buying an additional 3,782 shares during the period. Parallel Advisors LLC boosted its stake in Astrazeneca PLC by 27.1% in the first quarter. Parallel Advisors LLC now owns 4,526 shares of the company’s stock valued at $138,000 after buying an additional 964 shares during the period. Finally, Westport Asset Management Inc. bought a new stake in Astrazeneca PLC during the second quarter valued at $170,000. Institutional investors and hedge funds own 14.18% of the company’s stock.
Astrazeneca PLC (NYSE:AZN) opened at 29.24 on Monday. Astrazeneca PLC has a 12 month low of $25.55 and a 12 month high of $35.60. The firm has a 50-day moving average price of $31.08 and a 200-day moving average price of $31.53. The stock has a market cap of $74.04 billion, a price-to-earnings ratio of 19.18 and a beta of 0.74.
Astrazeneca PLC (NYSE:AZN) last released its quarterly earnings data on Thursday, July 27th. The company reported $0.87 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.41 by $0.46. The business had revenue of $5.05 billion during the quarter, compared to analysts’ expectations of $5.04 billion. Astrazeneca PLC had a return on equity of 35.90% and a net margin of 17.80%. The business’s quarterly revenue was down 9.9% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.83 EPS. Equities research analysts expect that Astrazeneca PLC will post $1.86 earnings per share for the current fiscal year.
The firm also recently disclosed a None dividend, which will be paid on Monday, September 11th. Stockholders of record on Friday, August 11th will be given a dividend of $0.44 per share. The ex-dividend date is Wednesday, August 9th. This represents a dividend yield of 2.98%. Astrazeneca PLC’s dividend payout ratio is currently 44.92%.
Several research firms recently weighed in on AZN. Piper Jaffray Companies reiterated a “buy” rating on shares of Astrazeneca PLC in a report on Wednesday, August 9th. BidaskClub cut shares of Astrazeneca PLC from a “sell” rating to a “strong sell” rating in a report on Friday, August 4th. Investec upgraded shares of Astrazeneca PLC from a “hold” rating to a “buy” rating in a report on Wednesday, August 9th. Cowen and Company reiterated a “hold” rating and issued a $34.00 price target on shares of Astrazeneca PLC in a report on Friday, July 28th. Finally, Pareto Securities upgraded shares of Astrazeneca PLC from a “sell” rating to a “hold” rating in a report on Tuesday, August 1st. Four equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating and eleven have assigned a buy rating to the stock. The stock has a consensus rating of “Hold” and an average price target of $33.39.
About Astrazeneca PLC
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Stock Ratings for Astrazeneca PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca PLC and related stocks with our FREE daily email newsletter.